At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 67 enrolled
Drug / intervention
Gemcitabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Trial of Gemcitabine (Gemzar) Plus ABI-007 (ABRAXANE) In Patients With Advanced Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating Gemcitabine and Albumin-bound paclitaxel for Metastatic Pancreatic Cancer. Completed, enrolled 67 participants across 5 sites.
Detailed Summary
To determine the maximum tolerated dose and dose-limiting toxicity of Gemcitabine plus Albumin-bound paclitaxel (ABI-007) in patients with advanced metastatic pancreatic cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedNov 2006
Primary CompletionSep 2008
Study CompletionDec 2010
TodayJul 2026
First PostedNov 10, 2006
Enrollment StartNov 1, 2006
Primary CompletionSep 1, 2008
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.6 years ago
Interventions
Gemcitabinedrug
Administered by intravenous infusion over 30 minutes.
Albumin-bound paclitaxeldrug
Administered by intravenous infusion over 30 minutes.